TrialSpark, which wants to leverage its clinical trials management software into drug discovery, closed $156M Series C at a $1B+ valuation earlier this year (Emma Court/Bloomberg)
Emma Court / Bloomberg:
TrialSpark, which wants to leverage its clinical trials management software into drug discovery, closed $156M Series C at a $1B+ valuation earlier this year — – TrialSpark expands from clinical trials into developing drugs — Company raised $156 million, is valued at more than $1 billion